Effects of Lovastatin on Proteinuria of Diabetic Nephropathy

Short-Term Effects of Lovastatin Therapy on Proteinuria of Type 2 Diabetic Nephropathy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012073010446N1

Enrollment

Registered

2012-08-08

Start date

2006-02-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proteinuria of Type 2 Diabetic Nephropathy. Glomerular disorders in diabetes mellitus

Interventions

Lovastatin (Ghazal Co, Tehran, Iran), in a dose of 20 mg/d, was administered to the patients for 90 days. At the end of the third month, the patients were asked to stop lovastatin intake from the 91st

Treatment - Drugs

Eligibility

Sex/Gender

Male

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Men with clinically documented T2DN were enrolled. To eliminate potential confounding factors, we only included patients with type 2 diabetes mellitus and proteinuria levels lower than the nephrotic range (i.e., 7.5%).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Change in Proteinuria level. Timepoint: (A) before lovastatin therapy (baseline), (B) after 45 days of lovastatin therapy (46th day), (C) after 90 days of lovastatin therapy (91st day), and (D) 30 days after the withdrawal of lovastatin therapy (121st day). Method of measurement: eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula. Twenty-four hour urine samples, Cr, and protein levels were assessed using coulorimetric and immunoturbidimetric methods.	—

Measure

Time frame

Change in Proteinuria level. Timepoint: (A) before lovastatin therapy (baseline), (B) after 45 days of lovastatin therapy (46th day), (C) after 90 days of lovastatin therapy (91st day), and (D) 30 days after the withdrawal of lovastatin therapy (121st day). Method of measurement: eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula. Twenty-four hour urine samples, Cr, and protein levels were assessed using coulorimetric and immunoturbidimetric methods.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Nariman Nezami

Drug Applied Research Center, Tabriz University (Medical Sciences),

dr.nezami@gmail.com+98 41 1333 8789

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026